Bevacizumab 5 mg/kg can be infused safely over 10 minutes

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2691-2695

  Reidy, Diane L ^a   Chung, Ki Y ^a   Timoney, John P ^a   Park, Vivian J ^a   Hollywood, Ellen ^a   Sklarin, Nancy T ^a   Muller, Raymond J ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DIPHENHYDRAMINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL; RANITIDINE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAST CANCER; CHILL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTRONIC MEDICAL RECORD; FEMALE; HOT FLUSH; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT IDENTIFICATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URTICARIA; VOMITING; DRUG ANTAGONISM; HYPERSENSITIVITY; MEDICAL RECORD; MIDDLE AGED; NEOPLASM; TIME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; NEOPLASMS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34447569438     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.3351     Document Type: Article

References (19)

1. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
2. Prewett M, Huber J, Li Y, et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209-5218, 1999
3. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
4. Giantonio BJ, Catalano PF, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
6. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
7. Miller KD, Wang M, Gralow J, et al: E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94, 2005 (suppl 1; abstr 3)
8. Raefsky EL, Spigel DR, Greco FA, et al: Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 23:633S, 2005 (abstr 7050)
9. Vokes EE, Cohen EEW, Mauer AM, et al: A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 23:501s, 2005 (abstr 5504)
10. Burger RA, Sill M, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 23:457S, 2005 (abstr 5009)
11. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
12. Giles FJ, Cortes JE, Halliburton TA, et al: Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother 37:1182-1185, 2003
13. Dillman RO: Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18:465-471, 1999
14. Timoney JP, Eagan MM, Sklarin NT: Establishing clinical guidelines for the management of acute hypersensitivity reactions secondary to the administration of chemotherapy/biologic therapy. J Nurs Care Qual 18:80-86, 2003
15. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 23:2S, 2005 (abstr LBA4)
16. Lu J, Gaudreault J, Novotny W, et al: A population pharmacokinetic model for bevacizumab. Clin Pharmacol Ther 75:91, 2004 (abstr PII-149)
17. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
19. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005